[en] The management of patients with hypertrophic cardiomyopathy has largely evolved over the past two decades. One important finding is that medical treatment appears under used. Invasive procedure are reserved to patients with obstructive hypertrophic cardiomyopathy who remain symptomatic despite optimal medical treatment. Indications for implantable cardiac defibrillator are still debated. A global and multidisciplinary approach of the patient and of his family is mandatory.
Disciplines :
Médecine générale & interne
Auteur, co-auteur :
Moonen, Marie ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
Pierard, Luc ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
Langue du document :
Français
Titre :
Actualités thérapeutiques dans la cardiomyopathie hypertrophique.
Titre traduit :
[en] New trends in treatment of hypertrophic cardiomyopathy.
Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: A position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-6.
Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92: 785-9.
Bos JM, Towbin JA, Ackerman MJ. Diagnostic prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:201-11.
* Maron BJ. Hypertrophic cardiomyopathy: A systematic review. JAMA 2002;287:1308-20.
Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral-based patient population. Circulation 2000;102:858-64.
** Hagège AA, Desnos M. New trends in treatment of hypertrophic cardiomyopathy. Arch Cardiovasc Dis 2009;102:441-7.
** Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents; European Society of Cardiology Committee for Practice Guidelines. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003;24:1965-91.
Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008;29:2388-442.
Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517-24. (Pubitemid 33107372)
Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/ AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:e1-62.
Moonen ML, Legrand V, Lancellotti P, et al. L'image du mois. Traitement percutané d'une cardiomyopathie hypertrophique obstructive. Rev Med Liege 2009;64: 481-3.
Hoffer E, Boland J. Traitement de la cardiomyopathie hypeitrophique obstructive par ablation septale percutanée. Rev Med Liege 2002;57:433-7.
